Stability-related studies on 17D yellow fever vaccine

被引:9
|
作者
Perraut, R [1 ]
Girault, G [1 ]
Moreau, JP [1 ]
机构
[1] Inst Pasteur, Yellow Fever Vaccine Unit, Dakar, Senegal
关键词
yellow fever; 17D vaccine; stability;
D O I
10.1016/S1286-4579(00)00288-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Yellow fever (YF) vaccine using the 17D strain of YF attenuated virus has been produced ar the Institut Pasteur in Dakar since 1962. Until now, the stabilised YF had an expiry date of utilisation of two years from the end of the lot control process under storage at + 4 degrees C. We conducted a stability study to assess the three full year validity of this preparation, when correctly stored at + 4 degrees C to optimise the conditions of production, storage and availability of such a vaccine. The activity of 19 consecutive batches of vaccines kept for three years at + 4 degrees C was compared to that of the same batches that were kept three years ar: -20 degrees C, Using the in vitro microculture method, we found that three-year storage at + 4 degrees C induced a higher loss of activity than storage at -20 degrees C or than the accelerated degradation test of vaccines kept for 14 days at 37 degrees C. Whatever the conditions of storage, in all cases decreases in activity were below the WHO's requirements, i.e., < 1 log PFU/dose, and residual activity of the selected batches was over 1000 mouse LD50 per dose. We demonstrated that the 17D YF vaccine produced in Dakar has a shelf-life of three years and that its required potency was maintained at + 4 degrees C, after reconstitution with saline diluent, following three-year storage at + 4 degrees C. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 50 条
  • [1] 17D Yellow Fever Virus Vaccine
    Monath, Thomas P.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1225 - 1225
  • [2] 17D Yellow Fever Virus Vaccine Response
    Edupuganti, Srilatha
    Mulligan, Mark J.
    Eidex, Rachel B.
    Cetron, Martin
    Marfin, Anthony A.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1226 - 1227
  • [3] Stability of 17D Yellow Fever virus vaccine using different stabilizers
    Adebayo, AA
    Sim-Brandenburg, JW
    Emmel, H
    Olaleye, DO
    Niedrig, M
    BIOLOGICALS, 1998, 26 (04) : 309 - 316
  • [4] STUDY OF THE STABILITY OF A NEW 17D THERMOSTABLE YELLOW-FEVER VACCINE
    DURAND, JP
    KOLLO, B
    MERLIN, M
    LEHESRAN, JY
    JOSSE, R
    GARRIGUE, GP
    JOURNAL OF BIOLOGICAL STANDARDIZATION, 1988, 16 (01): : 1 - 7
  • [5] Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly
    Monath, Thomas P.
    Cetron, Martin S.
    McCarthy, Karen
    Nichols, Richard
    Archambault, W. Tad
    Weld, Leisa
    Bedford, Philip
    HUMAN VACCINES, 2005, 1 (05): : 207 - 214
  • [6] Antibody response 17D yellow fever vaccine in Ghanaian infants
    Osei-Kwasi, M
    Dunyo, SK
    Koram, KA
    Afari, EA
    Odoom, JK
    Nkrumah, FK
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2001, 79 (11) : 1056 - 1059
  • [7] THERMAL-STABILITY OF A STABILIZED 17D YELLOW-FEVER VIRUS-VACCINE
    BURFOOT, C
    YOUNG, PA
    FINTER, NB
    JOURNAL OF BIOLOGICAL STANDARDIZATION, 1977, 5 (03): : 173 - 179
  • [8] VACCINATION BY SCARIFICATION WITH A COMBINED 17D YELLOW FEVER AND VACCINIA VACCINE
    DICK, GWA
    HORGAN, ES
    JOURNAL OF HYGIENE, 1952, 50 (03) : 376 - 383
  • [9] Neurovirulence tests of three 17D yellow fever vaccine strains
    Minor, Philip D.
    BIOLOGICALS, 2011, 39 (03) : 167 - 170
  • [10] Does yellow fever 17D vaccine protect against melanoma?
    Mastrangelo, G.
    Krone, B.
    Fadda, E.
    Buja, A.
    Grange, J. M.
    Rausa, G.
    de Vries, E.
    Koelmel, K. F.
    VACCINE, 2009, 27 (04) : 588 - 591